Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ERYTECH Pharma S.A.

https://erytech.com/

Latest From ERYTECH Pharma S.A.

Eight Oncology Drug Launches Expected In 2022 – Solid Tumors

In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are eight new oncology products to treat solid tumors that could make their market debuts next year.

Approvals Cancer

12 Key Oncology Drug Launches Expected In 2022 – Hematological Malignancies

In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are 12 new oncology products developed to treat hematological malignancies that, if successful at the regulators, are due to be launched for the first time next year.

Approvals Companies

France's Erytech Closer To Realizing Market Ambitions With Eryaspase US Filing

It has taken almost two decades but it looks as though Erytech could get approval for eryaspase in the US in two indications next year – acute lymphoblastic leukemia and pancreatic cancer.

Cancer Business Strategies

Retrophin Bolsters Portfolio With Orphan Technologies Buyout

The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • ERYTECH Pharma, Inc.
UsernamePublicRestriction

Register